title: Recombinant human endostatin (endostar) decreased recurrent ascites, pleural fluid and ascitic VEGF in a case of advanced mesothelioma.
abstract: We report a case of 43-year-old male with advanced malignant mesothelioma (MM) with a large amount of fluid in the pleural and peritoneal cavity. The addition of endostar to the gemcitabine-cisplatin regimen gave a prompt and significant improvement of clinical symptoms and disappearance  of ascites. The patient is still progression free after 27 months. Endostar, in combination with chemotherapy should be explored in the treatment of MM, especially its effect on pleural and ascitic fluid.
authors.affiliation: Department of Oncology, First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
authors.forename: Xiaofeng
authors.initials: X
authors.lastname: Chen
authors.forename: Yiqian
authors.initials: Y
authors.lastname: Liu
authors.forename: Yongmei
authors.initials: Y
authors.lastname: Yin
authors.forename: Shidai
authors.initials: S
authors.lastname: Jin
authors.forename: Guoqian
authors.initials: G
authors.lastname: Ping
authors.forename: Oluf D
authors.initials: OD
authors.lastname: Røe
authors.forename: Keli
authors.initials: K
authors.lastname: Yan
authors.forename: Yongqian
authors.initials: Y
authors.lastname: Shu
authors.forename: Renhua
authors.initials: R
authors.lastname: Guo
mesh_terms: D000328:Adult; D020533:Angiogenesis Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001201:Ascites / Q000209:etiology / Q000503:physiopathology / Q000517:prevention & control*; D001202:Ascitic Fluid / Q000378:metabolism*; D002945:Cisplatin / Q000008:administration & dosage / Q000627:therapeutic use; D003841:Deoxycytidine / Q000008:administration & dosage / Q000031:analogs & derivatives / Q000627:therapeutic use; D019008:Drug Resistance, Neoplasm; D043169:Endostatins / Q000008:administration & dosage / Q000627:therapeutic use*; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology / Q000503:physiopathology; D008297:Male; D008654:Mesothelioma / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology / Q000503:physiopathology; D000086002:Mesothelioma, Malignant; D009367:Neoplasm Staging; D016066:Pleural Effusion, Malignant / Q000517:prevention & control*; D011994:Recombinant Proteins / Q000008:administration & dosage / Q000627:therapeutic use; D055502:Secondary Prevention; D012720:Severity of Illness Index; D016896:Treatment Outcome; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors / Q000378:metabolism*; D000093542:Gemcitabine
chemical_list: D020533:Angiogenesis Inhibitors; D043169:Endostatins; D011994:Recombinant Proteins; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A; D003841:Deoxycytidine; C522911:endostar protein; D002945:Cisplatin; D000093542:Gemcitabine